PART 15 U.K.Amendment of Part 14 (advertising)

Amendment of regulation 279 (products without a marketing authorisation) U.K.

[F1 211.  For regulation 279 substitute—

“279.— (1) A person may not publish an advertisement in Great Britain for a medicinal product unless one of the following is in force for the product—

(a) a UKMA(GB) or UKMA(UK);

(b) a COR(GB) or COR(UK); or

(c) a THR(GB) or THR(UK).

(2) A person may not publish an advertisement in Northern Ireland for a medicinal product unless one of the following is in force for the product—

(a) a UKMA(NI) or UKMA(UK);

(b) a COR(NI) or COR(UK);

(c) a THR(NI) or THR(UK);

(d) an EU marketing authorisation; or

(e) an Article 126a authorisation.

(3) A person may not publish an advertisement in the whole United Kingdom for a medicinal product unless, in relation to that product—

(a) one of the authorisations or registrations specified in paragraph (1) is in force in Great Britain; and

(b) one of the authorisations or registrations specified in paragraph (2) is in force in Northern Ireland.”.]

Textual Amendments

F1 Reg. 211 substituted (31.12.2020 immediately before IP completion day) by The Human Medicines (Amendment etc.) (EU Exit) Regulations 2020 (S.I. 2020/1488), reg. 1, Sch. 2 para. 167

Commencement Information

I1 Reg. 211 in force at 31.12.2020 on IP completion day (in accordance with 2020 c. 1, Sch. 5 para. 1(1)), see reg. 1

Amendment of regulation 280 (general principles) U.K.

212.  In regulation [F2 280] —

(a) [F3 in paragraph (1)] for “marketing authorisation,” substitute “ [F4 UK marketing authorisation, EU marketing authorisation,] ”; and

[F5 (b) after paragraph (1) insert—

“(1A) Where an advertisement mentioned in paragraph (1) relates to a product in relation to which there is a separate authorisation or registration in force in Great Britain and in Northern Ireland, it may not be published in the whole United Kingdom unless it complies with the particulars listed in the summary of the product characteristics in each of those authorisations or registrations (as the case may be).”.]

Textual Amendments

F2 Word in reg. 212 substituted (31.12.2020 immediately before IP completion day) by The Human Medicines (Amendment etc.) (EU Exit) Regulations 2020 (S.I. 2020/1488), reg. 1, Sch. 2 para. 168(a)

F3 Words in reg. 212(a) inserted (31.12.2020 immediately before IP completion day) by The Human Medicines (Amendment etc.) (EU Exit) Regulations 2020 (S.I. 2020/1488), reg. 1, Sch. 2 para. 168(b)(i)

F4 Words in reg. 212(a) substituted (31.12.2020 immediately before IP completion day) by The Human Medicines (Amendment etc.) (EU Exit) Regulations 2020 (S.I. 2020/1488), reg. 1, Sch. 2 para. 168(b)(ii)

F5 Reg. 212(b) substituted (31.12.2020 immediately before IP completion day) by The Human Medicines (Amendment etc.) (EU Exit) Regulations 2020 (S.I. 2020/1488), reg. 1, Sch. 2 para. 168(c)

Commencement Information

I2 Reg. 212 in force at 31.12.2020 on IP completion day (in accordance with 2020 c. 1, Sch. 5 para. 1(1)), see reg. 1

Amendment of regulation 281 (duties of authorisation holders and registration holders) U.K.

213.  In regulation 281(1)—

(a) in sub-paragraph (a), insert “ UK ” before “marketing authorisation”;

[F6 (b) omit “or” at the end of sub-paragraph (c); and

(c) in sub-paragraph (d), after “for a medicinal product” insert—

“; or

(e) an EU marketing authorisation for a medicinal product.”.]

Textual Amendments

F6 Reg. 213(b)(c) substituted (31.12.2020 immediately before IP completion day) by The Human Medicines (Amendment etc.) (EU Exit) Regulations 2020 (S.I. 2020/1488), reg. 1, Sch. 2 para. 169

Commencement Information

I3 Reg. 213 in force at 31.12.2020 on IP completion day (in accordance with 2020 c. 1, Sch. 5 para. 1(1)), see reg. 1

[F7 Insertion of new regulation 284A (Medicines with differing classification status in Great Britain and Northern Ireland) U.K.

213A.   After regulation 284, insert—

“Medicines with differing classification status in Great Britain and Northern Ireland

284A.   In the case of a medicinal product for sale or supply in Great Britain where the product concerned is not a prescription only medicine in Great Britain but is either—

(a) a prescription only medicine in Northern Ireland; or

(b) not authorised for sale or supply in Northern Ireland,

any advertisement to the public must include a statement that the medicinal product is not available without a prescription, or is not available for sale or supply, in Northern Ireland (as the case may be).”.]

Textual Amendments

F7 Reg. 213A inserted (31.12.2020 immediately before IP completion day) by The Human Medicines (Amendment etc.) (EU Exit) Regulations 2020 (S.I. 2020/1488), reg. 1, Sch. 2 para. 170

Commencement Information

I4 Reg. 213A in force at 31.12.2020 on IP completion day (in accordance with 2020 c. 1, Sch. 5 para. 1(1)), see reg. 1

Amendment of regulation 293 (prohibition of supply to the public for promotional purposes) U.K.

[F8 214.   For regulation 293(1) substitute—

“(1) The holder of—

(a) in the case of a medicinal product for sale or supply in Great Britain, a UKMA(GB), UKMA(UK), COR(GB), COR(UK), THR(GB) or THR(UK); or

(b) in the case of a medicinal product for sale or supply in Northern Ireland, a UKMA(NI), UKMA(UK), COR(NI), COR(UK), THR(NI), THR(UK), EU marketing authorisation or Article 126a authorisation,

may not sell or supply a medicinal product for a promotional purpose to a person who is not qualified to prescribe medicinal products.”.]

Textual Amendments

F8 Reg. 214 substituted (31.12.2020 immediately before IP completion day) by The Human Medicines (Amendment etc.) (EU Exit) Regulations 2020 (S.I. 2020/1488), reg. 1, Sch. 2 para. 171

Commencement Information

I5 Reg. 214 in force at 31.12.2020 on IP completion day (in accordance with 2020 c. 1, Sch. 5 para. 1(1)), see reg. 1

[F9 Amendment of regulation 294 (general requirements) U.K.

214A.   In regulation 294, after paragraph (4) insert—

“(5) In the case of an advertisement which relates to a medicinal product for sale or supply—

(a) in Northern Ireland only, the requirements of this regulation must be met in relation to the product for sale or supply in Northern Ireland,

(b) in Great Britain only, the requirements of this regulation must be met in relation to the product for sale or supply in Great Britain, and

(c) in the whole of the United Kingdom, the requirements of this regulation must be met in relation to both—

(i) the product for sale or supply in Great Britain, and

(ii) the product for sale or supply in Northern Ireland.”.]

Textual Amendments

F9 Reg. 214A inserted (31.12.2020 immediately before IP completion day) by The Human Medicines (Amendment etc.) (EU Exit) Regulations 2020 (S.I. 2020/1488), reg. 1, Sch. 2 para. 172

Commencement Information

I6 Reg. 214A in force at 31.12.2020 on IP completion day (in accordance with 2020 c. 1, Sch. 5 para. 1(1)), see reg. 1

Amendment of regulation 295 (abbreviated advertisements) U.K.

[F10 215.   In regulation 295—

(a) for paragraph (2)(d) substitute—

“(d) the name and address of the holder—

(i) in the case of a medicinal product for sale or supply in Great Britain, of the UKMA(GB), UKMA(UK), COR(GB), COR(UK), THR(GB) or THR(UK) for the medicinal product, or

(ii) in the case of a medicinal product for sale or supply in Northern Ireland, the name and address of the holder of the UKMA(NI), UKMA(UK), COR(NI), COR(UK), THR(NI), THR(UK), EU marketing authorisation, or Article 126a authorisation for the medicinal product,

or the business name and address of the part of the holder’s business that is responsible for the sale or supply of the medicinal product.”;

(b) after paragraph (4) insert—

“(4A) In the application of this regulation to a medicinal product for sale or supply—

(a) in Northern Ireland only, the requirements of this regulation must be met in relation to the product for sale or supply in Northern Ireland,

(b) in Great Britain only, the requirements of this regulation must be met in relation to the product for sale or supply in Great Britain, and

(c) in the whole of the United Kingdom, the requirements of this regulation must be met in relation to both—

(i) the product for sale or supply in Great Britain, and

(ii) the product for sale or supply in Northern Ireland.”.]

Textual Amendments

F10 Reg. 215 substituted (31.12.2020 immediately before IP completion day) by The Human Medicines (Amendment etc.) (EU Exit) Regulations 2020 (S.I. 2020/1488), reg. 1, Sch. 2 para. 173

Commencement Information

I7 Reg. 215 in force at 31.12.2020 on IP completion day (in accordance with 2020 c. 1, Sch. 5 para. 1(1)), see reg. 1

[F11 Amendment of regulation 298 (free samples for persons qualified to prescribe or supply medicinal products) U.K.

215A.   In regulation 298, for paragraph (5)(a) substitute—

“(a) is no larger than the smallest presentation of the product that is available for sale—

(i) in the case of a medicinal product for sale or supply in Great Britain, in Great Britain, or

(ii) in the case of a medicinal product for sale or supply in Northern Ireland, in Northern Ireland;”.]

Textual Amendments

F11 Reg. 215A inserted (31.12.2020 immediately before IP completion day) by The Human Medicines (Amendment etc.) (EU Exit) Regulations 2020 (S.I. 2020/1488), reg. 1, Sch. 2 para. 174

Commencement Information

I8 Reg. 215A in force at 31.12.2020 on IP completion day (in accordance with 2020 c. 1, Sch. 5 para. 1(1)), see reg. 1

Amendment of Schedule 30 (particulars for advertisements to persons qualified to prescribe or supply) U.K.

[F12 216.   In Schedule 30—

(a) in paragraphs 1, 2 and 6, for “marketing authorisation,” substitute “UK marketing authorisation, EU marketing authorisation”;

(b) after paragraph 2 insert—

“2A.   In relation to an advertisement in Great Britain (other than an advertisement falling within the exception in regulation 296) where the medicinal product concerned is authorised under a UKMA(GB), a statement that the product concerned is authorised under a UKMA(GB).”.]

Textual Amendments

F12 Reg. 216 substituted (31.12.2020 immediately before IP completion day) by The Human Medicines (Amendment etc.) (EU Exit) Regulations 2020 (S.I. 2020/1488), reg. 1, Sch. 2 para. 175

Commencement Information

I9 Reg. 216 in force at 31.12.2020 on IP completion day (in accordance with 2020 c. 1, Sch. 5 para. 1(1)), see reg. 1

Amendment of regulation 299 (medical sales representatives) U.K.

217.  In regulation 299(3), [F13 for “marketing authorisation,” substitute “UK marketing authorisation, EU marketing authorisation”.]

Textual Amendments

F13 Words in reg. 217 substituted (31.12.2020 immediately before IP completion day) by The Human Medicines (Amendment etc.) (EU Exit) Regulations 2020 (S.I. 2020/1488), reg. 1, Sch. 2 para. 176

Commencement Information

I10 Reg. 217 in force at 31.12.2020 on IP completion day (in accordance with 2020 c. 1, Sch. 5 para. 1(1)), see reg. 1

[F14 Amendment of regulation 305 (invitation to make representations about compatibility) U.K.

217A.   In regulation 305—

(a) for paragraph (3)(a) substitute—

“(a) state that the Ministers are minded to make a determination under regulation 306 that the advertisement is incompatible with the prohibitions imposed by Chapter 2 and specify whether the incompatibility is insofar as the advertisement is for publication—

(i) in Great Britain;

(ii) in Northern Ireland; or

(iii) in both Great Britain and Northern Ireland;”;

(b) in paragraph (4), after “the advertisement” insert—

“—

(a) in Great Britain;

(b) in Northern Ireland; or

(c) in both Great Britain and Northern Ireland”.

Textual Amendments

F14 Regs. 217A-217D inserted (31.12.2020 immediately before IP completion day) by The Human Medicines (Amendment etc.) (EU Exit) Regulations 2020 (S.I. 2020/1488), reg. 1, Sch. 2 para. 177

Commencement Information

I11 Reg. 217A in force at 31.12.2020 on IP completion day (in accordance with 2020 c. 1, Sch. 5 para. 1(1)), see reg. 1

Amendment of regulation 306 (decision about compatibility) U.K.

217B.   In regulation 306—

(a) in paragraph (2), after “Chapter 2” insert—

“and specify whether the incompatibility is insofar as the advertisement is for publication—

(a) in Great Britain;

(b) in Northern Ireland; or

(c) in both Great Britain and Northern Ireland”;

(b) in paragraph (4)—

(i) in sub-paragraph (a), after “Chapter 2” insert—

“insofar as the advertisement is for publication—

(i) in Great Britain;

(ii) in Northern Ireland; or

(iii) in both Great Britain and Northern Ireland”;

(ii) after “no longer applies” insert “in Great Britain, Northern Ireland, or both Great Britain and Northern Ireland (as appropriate)”;

(c) in paragraph (5), after “Chapter 2” insert—

“insofar as the advertisement is for publication—

(a) in Great Britain;

(b) in Northern Ireland; or

(c) in both Great Britain and Northern Ireland”;

(d) in paragraph (7)(b), after “no longer applies” insert—

• “,

and where that original notice related to both Great Britain and Northern Ireland, the new notice may be expressed to apply in relation to either of or both Great Britain and Northern Ireland”;

(e) in paragraph (8), after “the advertisement” insert—

“—

(a) in Great Britain;

(b) in Northern Ireland; or

(c) in both Great Britain and Northern Ireland”.

Textual Amendments

F14 Regs. 217A-217D inserted (31.12.2020 immediately before IP completion day) by The Human Medicines (Amendment etc.) (EU Exit) Regulations 2020 (S.I. 2020/1488), reg. 1, Sch. 2 para. 177

Commencement Information

I12 Reg. 217B in force at 31.12.2020 on IP completion day (in accordance with 2020 c. 1, Sch. 5 para. 1(1)), see reg. 1

Amendment of regulation 307 (corrective statement) U.K.

217C.   In regulation 307—

(a) in paragraph (1)(a), after “subject of the notice” insert—

“in—

(i) Great Britain;

(ii) Northern Ireland; or

(iii) both Great Britain and Northern Ireland”;

(b) in paragraph (1)(b), after “that advertisement” insert—

“in—

(i) Great Britain;

(ii) Northern Ireland; or

(iii) both Great Britain and Northern Ireland”;

(c) in paragraph (2)(a), for “, either in full or in part; and” substitute—

“in respect of—

(i) Great Britain;

(ii) Northern Ireland; or

(iii) both Great Britain and Northern Ireland,

either in full or in part; and”.

Textual Amendments

F14 Regs. 217A-217D inserted (31.12.2020 immediately before IP completion day) by The Human Medicines (Amendment etc.) (EU Exit) Regulations 2020 (S.I. 2020/1488), reg. 1, Sch. 2 para. 177

Commencement Information

I13 Reg. 217C in force at 31.12.2020 on IP completion day (in accordance with 2020 c. 1, Sch. 5 para. 1(1)), see reg. 1

Amendment of regulation 311 (application for injunction) U.K.

217D.   In regulation 311—

(a) in paragraph (1)(a), for “Chapter 2; and” substitute—

“Chapter 2 in respect of—

(i) Great Britain;

(ii) Northern Ireland; or

(iii) both Great Britain and Northern Ireland; and”;

(b) in paragraph (3), after “ the advertisement” insert—

“in—

(i) Great Britain;

(ii) Northern Ireland; or

(iii) both Great Britain and Northern Ireland,

as the case may be.”.]

Textual Amendments

F14 Regs. 217A-217D inserted (31.12.2020 immediately before IP completion day) by The Human Medicines (Amendment etc.) (EU Exit) Regulations 2020 (S.I. 2020/1488), reg. 1, Sch. 2 para. 177

Commencement Information

I14 Reg. 217D in force at 31.12.2020 on IP completion day (in accordance with 2020 c. 1, Sch. 5 para. 1(1)), see reg. 1